Intravenous administration of the liposomal formulation complexed with GIPC1 siRNA inhibited tumor growth and significantly increased the GEM sensitivity in orthotopic pancreatic xenografts compared to that for the untreated control group. Here, GIPC1 is linked to neoplasm.